Optimizing the Use of Antibacterial Agents in the Neonatal Period

Pediatric Drugs

Volumn 18, Issue 2, 2016, Pages 109-122

  Cantey, Joseph B ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADVERSE OUTCOME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CONTINUOUS INFUSION; COST CONTROL; DRUG COST; DRUG USE; HUMAN; INFECTION PREVENTION; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN CARE; NEWBORN INFECTION; NEWBORN MORTALITY; NEWBORN SEPSIS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; DRUG THERAPY; NEONATAL INTENSIVE CARE UNIT; SEPSIS; STANDARDS;

ANTI-BACTERIAL AGENTS; DRUG THERAPY; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; SEPSIS;

EID: 84953387529     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-015-0161-1     Document Type: Article

References (172)

1. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–72.
2. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285–91.
3. Stoll BJ, Hansen NI, Sanchez PJ, Faix RG, Poindexter BB, Van Meurs KP, et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817–26.
4. Wirtschafter DD, Padilla G, Suh O, Wan K, Trupp D, Fayard EE. Antibiotic use for presumed neonatally acquired infections far exceeds that for central line-associated blood stream infections: an exploratory critique. J Perinatol. 2011;31(8):514–8.
5. Cantey JB, Wozniak PS, Sanchez PJ. Prospective surveillance of antibiotic use in the neonatal intensive care unit: results from the SCOUT Study. Pediatr Infect Dis J. 2015;34(3):267–72.
6. Patel SJ, Oshodi A, Prasad P, Delamora P, Larson E, Zaoutis T, et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J. 2009;28(12):1047–51.
7. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117(6):1979–87.
8. Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB. Neonatal intensive care unit antibiotic use. Pediatrics. 2015;135(5):826–33.
9. Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB, et al. Medication use in the neonatal intensive care unit. Am J Perinatol. 2014;31(9):811–21.
10. Torrazza RM, Neu J. The altered gut microbiome and necrotizing enterocolitis. Clin Perinatol. 2013;40(1):93–108.
11. Shah P, Nathan E, Doherty D, Patole S. Prolonged exposure to antibiotics and its associations in extremely preterm neonates: the Western Australian experience. J Matern Fetal Neonatal Med. 2013;26(17):1710–4.
12. Mai V, Young CM, Ukhanova M, Wang X, Sun Y, Casella G, et al. Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS One. 2011;6(6):e20647.
13. Kuppala VS, Meinzen-Derr J, Morrow AL, Schibler KR. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr. 2011;159(5):720–5.
14. Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, Sanchez PJ, et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics. 2009;123(1):58–66.
15. Saiman L, Ludington E, Dawson JD, Patterson JE, Rangel-Frausto S, Wiblin RT, et al. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J. 2001;20(12):1119–24.
16. Alexander VN, Northrup V, Bizzarro MJ. Antibiotic exposure in the newborn intensive care unit and the risk of necrotizing enterocolitis. J Pediatr. 2011;159(3):392–7.
17. Cotten CM, McDonald S, Stoll B, Goldberg RN, Poole K, Benjamin DK Jr. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118(2):717–22.
18. Teo SM, Mok D, Pham K, Kusel M, Serralha M, Troy N, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe. 2015;17(5):704–15.
19. Saari A, Virta LJ, Sankilampi U, Dunkel L, Saxen H. Antibiotic exposure in infancy and risk of being overweight in the first 24 months of life. Pediatrics. 2015;135(4):617–26.
20. Wegienka G, Havstad S, Zoratti EM, Kim H, Ownby DR, Johnson CC. Combined effects of prenatal medication use and delivery type are associated with eczema at age 2 years. Clin Exp Allergy. 2015;45(3):660–8.
21. de Man P, Verhoeven BA, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet. 2000;355(9208):973–8.
22. Cantey JB, Milstone AM. Bloodstream infections: epidemiology and resistance. Clin Perinatol. 2015;42(1):1–16 (vii).
23. Bizzarro MJ, Gallagher PG. Antibiotic-resistant organisms in the neonatal intensive care unit. Semin Perinatol. 2007;31(1):26–32.
24. Tsai MH, Chu SM, Hsu JF, Lien R, Huang HR, Chiang MC, et al. Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU. Pediatrics. 2014;133(2):e322–9.
25. Huang Y, Zhuang S, Du M. Risk factors of nosocomial infection with extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit in China. Infection. 2007;35(5):339–45.
26. Toltzis P. Colonization with antibiotic-resistant Gram-negative bacilli in the neonatal intensive care unit. Minerva Pediatr. 2003;55(5):385–93.
27. Cantey JB, Patel SJ. Antimicrobial stewardship in the NICU. Infect Dis Clin N Am. 2014;28(2):247–61.
28. Azab SF, Sherbiny HS, Saleh SH, Elsaeed WF, Elshafiey MM, Siam AG, et al. Reducing ventilator-associated pneumonia in neonatal intensive care unit using “VAP prevention Bundle”: a cohort study. BMC Infect Dis. 2015;15:314.
29. Fisher D, Cochran KM, Provost LP, Patterson J, Bristol T, Metzguer K, et al. Reducing central line-associated bloodstream infections in North Carolina NICUs. Pediatrics. 2013;132(6):e1664–71.
30. Rosenthal VD, Duenas L, Sobreyra-Oropeza M, Ammar K, Navoa-Ng JA, de Casares AC, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part III: effectiveness of a multidimensional infection control approach to reduce central line-associated bloodstream infections in the neonatal intensive care units of 4 developing countries. Infect Control Hosp Epidemiol. 2013;34(3):229–37.
31. Rosenthal VD, Rodriguez-Calderon ME, Rodriguez-Ferrer M, Singhal T, Pawar M, Sobreyra-Oropeza M, et al. Findings of the International Nosocomial Infection Control Consortium (INICC), part II: impact of a multidimensional strategy to reduce ventilator-associated pneumonia in neonatal intensive care units in 10 developing countries. Infect Control Hosp Epidemiol. 2012;33(7):704–10.
32. Schulman J, Stricof R, Stevens TP, Horgan M, Gase K, Holzman IR, et al. Statewide NICU central-line-associated bloodstream infection rates decline after bundles and checklists. Pediatrics. 2011;127(3):436–44.
33. Greenberg RG, Cochran KM, Smith PB, Edson BS, Schulman J, Lee HC, et al. Effect of catheter dwell time on risk of central line-associated bloodstream infection in infants. Pediatrics. 2015;136(6):1080–6.
34. Wojkowska-Mach J, Rozanska A, Borszewska-Kornacka M, Domanska J, Gadzinowski J, Gulczynska E, et al. Necrotising enterocolitis in preterm infants: epidemiology and antibiotic consumption in the Polish neonatology network neonatal intensive care units in 2009. PLoS One. 2014;9(3):e92865.
35. Patel AL, Trivedi S, Bhandari NP, Ruf A, Scala CM, Witowitch G, et al. Reducing necrotizing enterocolitis in very low birth weight infants using quality-improvement methods. J Perinatol. 2014;34(11):850–7.
36. Patole SK, de Klerk N. Impact of standardised feeding regimens on incidence of neonatal necrotising enterocolitis: a systematic review and meta-analysis of observational studies. Arch Dis Child Fetal Neonatal Ed. 2005;90(2):F147–51.
37. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O’Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol. 2007;27(7):428–33.
38. Cristofalo EA, Schanler RJ, Blanco CL, Sullivan S, Trawoeger R, Kiechl-Kohlendorfer U, et al. Randomized trial of exclusive human milk versus preterm formula diets in extremely premature infants. J Pediatr. 2013;163(6):1592–5 (e1).
39. Mukerji A, Narciso J, Moore C, McGeer A, Kelly E, Shah V. An observational study of the hand hygiene initiative: a comparison of preintervention and postintervention outcomes. BMJ Open. 2013;3(5):e003018.
40. Harris AD, Pineles L, Belton B, Johnson JK, Shardell M, Loeb M, et al. Universal glove and gown use and acquisition of antibiotic-resistant bacteria in the ICU: a randomized trial. JAMA. 2013;310(15):1571–80.
41. Huskins WC, Huckabee CM, O’Grady NP, Murray P, Kopetskie H, Zimmer L, et al. Intervention to reduce transmission of resistant bacteria in intensive care. N Engl J Med. 2011;364(15):1407–18.
42. Kaufman DA, Blackman A, Conaway MR, Sinkin RA. Nonsterile glove use in addition to hand hygiene to prevent late-onset infection in preterm infants: randomized clinical trial. JAMA Pediatr. 2014;168(10):909–16.
43. Cantey JB, Ronchi A, Sanchez PJ. Spreading the benefits of infection prevention in the Neonatal Intensive Care Unit. JAMA Pediatr. 2015;169(12):1089–91.
44. Rybczynska H, Melander E, Johansson H, Lundberg F. Efficacy of a once-a-week screening programme to control extended-spectrum beta-lactamase-producing bacteria in a neonatal intensive care unit. Scand J Infect Dis. 2014;46(6):426–32.
45. Macnow T, O’Toole D, DeLaMora P, Murray M, Rivera K, Whittier S, et al. Utility of surveillance cultures for antimicrobial resistant organisms in infants transferred to the neonatal intensive care unit. Pediatr Infect Dis J. 2013;32(12):e443–50.
46. Milstone AM, Maragakis LL, Carroll KC, Perl TM. Targeted surveillance to identify children colonized with vancomycin-resistant Enterococcus in the pediatric intensive care unit. Infect Control Hosp Epidemiol. 2010;31(1):95–8.
47. Popoola VO, Budd A, Wittig SM, Ross T, Aucott SW, Perl TM, et al. Methicillin-resistant Staphylococcus aureus transmission and infections in a neonatal intensive care unit despite active surveillance cultures and decolonization: challenges for infection prevention. Infect Control Hosp Epidemiol. 2014;35(4):412–8.
48. Chapman AK, Aucott SW, Gilmore MM, Advani S, Clarke W, Milstone AM. Absorption and tolerability of aqueous chlorhexidine gluconate used for skin antisepsis prior to catheter insertion in preterm neonates. J Perinatol. 2013;33(10):768–71.
49. Bringue Espuny X, Soria X, Sole E, Garcia J, Marco JJ, Ortega J, et al. Chlorhexidine-methanol burns in two extreme preterm newborns. Pediatr Dermatol. 2010;27(6):676–8.
50. Johnson RC, Schlett CD, Crawford K, Lanier JB, Merrell DS, Ellis MW. Recurrent methicillin-resistant Staphylococcus aureus cutaneous abscesses and selection of reduced chlorhexidine susceptibility during chlorhexidine use. J Clin Microbiol. 2015;53(11):3677–82.
51. Ichikawa K, Fujiwara T, Nakayama T. Effectiveness of home visits in pregnancy as a public health measure to improve birth outcomes. PLoS One. 2015;10(9):e0137307.
52. McLaughlin FJ, Altemeier WA, Christensen MJ, Sherrod KB, Dietrich MS, Stern DT. Randomized trial of comprehensive prenatal care for low-income women: effect on infant birth weight. Pediatrics. 1992;89(1):128–32.
53. Shah NR, Bracken MB. A systematic review and meta-analysis of prospective studies on the association between maternal cigarette smoking and preterm delivery. Am J Obstet Gynecol. 2000;182(2):465–72.
54. Sangkomkamhang US, Lumbiganon P, Prasertcharoensuk W, Laopaiboon M. Antenatal lower genital tract infection screening and treatment programs for preventing preterm delivery. Cochrane Database Syst Rev. 2015;2:CD006178.
55. Dodd JM, Jones L, Flenady V, Cincotta R, Crowther CA. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev. 2013;7:CD004947.
56. Bekhof J, Reitsma JB, Kok JH, Van Straaten IH. Clinical signs to identify late-onset sepsis in preterm infants. Eur J Pediatr. 2013;172(4):501–8.
57. Fischer JE. Physicians’ ability to diagnose sepsis in newborns and critically ill children. Pediatr Crit Care Med. 2005;6(3 Suppl):S120–5.
58. Ottolini MC, Lundgren K, Mirkinson LJ, Cason S, Ottolini MG. Utility of complete blood count and blood culture screening to diagnose neonatal sepsis in the asymptomatic at risk newborn. Pediatr Infect Dis J. 2003;22(5):430–4.
59. DiGeronimo RJ. Lack of efficacy of the urine culture as part of the initial workup of suspected neonatal sepsis. Pediatr Infect Dis J. 1992;11(9):764–6.
60. Visser VE, Hall RT. Urine culture in the evaluation of suspected neonatal sepsis. J Pediatr. 1979;94(4):635–8.
61. Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595–610.
62. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics. 2004;113(5):1181–6.
63. Flidel-Rimon O, Leibovitz E, Eventov Friedman S, Juster-Reicher A, Shinwell ES. Is lumbar puncture (LP) required in every workup for suspected late-onset sepsis in neonates? Acta Paediatr. 2011;100(2):303–4.
64. Kliegman RM, Walsh MC. The incidence of meningitis in neonates with necrotizing enterocolitis. Am J Perinatol. 1987;4(3):245–8.
65. Hendricks-Munoz KD, Shapiro DL. The role of the lumbar puncture in the admission sepsis evaluation of the premature infant. J Perinatol. 1990;10(1):60–4.
66. Weiss MG, Ionides SP, Anderson CL. Meningitis in premature infants with respiratory distress: role of admission lumbar puncture. J Pediatr. 1991;119(6):973–5.
67. Dietzman DE, Fischer GW, Schoenknecht FD. Neonatal Escherichia coli septicemia: bacterial counts in blood. J Pediatr. 1974;85(1):128–30.
68. Schelonka RL, Chai MK, Yoder BA, Hensley D, Brockett RM, Ascher DP. Volume of blood required to detect common neonatal pathogens. J Pediatr. 1996;129(2):275–8.
69. Connell TG, Rele M, Cowley D, Buttery JP, Curtis N. How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children’s hospital. Pediatrics. 2007;119(5):891–6.
70. Kellogg JA, Ferrentino FL, Goodstein MH, Liss J, Shapiro SL, Bankert DA. Frequency of low level bacteremia in infants from birth to two months of age. Pediatr Infect Dis J. 1997;16(4):381–5.
71. Polin RA, Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129(5):1006–15.
72. Sarkar S, Bhagat I, DeCristofaro JD, Wiswell TE, Spitzer AR. A study of the role of multiple site blood cultures in the evaluation of neonatal sepsis. J Perinatol. 2006;26(1):18–22.
73. Seybold U, Reichardt C, Halvosa JS, Blumberg HM. Clonal diversity in episodes with multiple coagulase-negative Staphylococcus bloodstream isolates suggesting frequent contamination. Infection. 2009;37(3):256–60.
74. Struthers S, Underhill H, Albersheim S, Greenberg D, Dobson S. A comparison of two versus one blood culture in the diagnosis and treatment of coagulase-negative staphylococcus in the neonatal intensive care unit. J Perinatol. 2002;22(7):547–9.
75. Healy CM, Baker CJ, Palazzi DL, Campbell JR, Edwards MS. Distinguishing true coagulase-negative Staphylococcus infections from contaminants in the neonatal intensive care unit. J Perinatol. 2013;33(1):52–8.
76. Centers for Disease Control and Prevention. Ventilator-associated event. 2016. http://www.cdc.gov/nhsn/PDFs/pscManual/10-VAE_FINAL.pdf. Accessed 9 Dec 2015.
77. Willson DF, Conaway M, Kelly R, Hendley JO. The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children. Pediatr Crit Care Med. 2014;15(4):299–305.
78. Willson DF, Kirby A, Kicker JS. Respiratory secretion analyses in the evaluation of ventilator-associated pneumonia: a survey of current practice in pediatric critical care. Pediatr Crit Care Med. 2014;15(8):715–9.
79. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355(25):2619–30.
80. Mikhael M, Brown LS, Rosenfeld CR. Serial neutrophil values facilitate predicting the absence of neonatal early-onset sepsis. J Pediatr. 2014;164(3):522–8 (e1–3).
81. Srinivasan L, Harris MC. New technologies for the rapid diagnosis of neonatal sepsis. Curr Opin Pediatr. 2012;24(2):165–71.
82. Bhandari V. Effective biomarkers for diagnosis of neonatal sepsis. J Pediatr Infect Dis Soc. 2014;3(3):234–45.
83. Ng PC, Ma TP, Lam HS. The use of laboratory biomarkers for surveillance, diagnosis and prediction of clinical outcomes in neonatal sepsis and necrotising enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2015;100(5):F448–52.
84. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R. The neonatal blood count in health and disease: I. Reference values for neutrophilic cells. J Pediatr. 1979;95(1):89–98.
85. Cantey JB, Sanchez PJ. Prolonged antibiotic therapy for “culture-negative” sepsis in preterm infants: it’s time to stop! J Pediatr. 2011;159(5):707–8.
86. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis. 2011;52(10):1232–40.
87. Cantey JB, Sreeramoju P, Jaleel M, Trevino S, Gander R, Hynan LS, et al. Prompt control of an outbreak caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. J Pediatr. 2013;163(3):672–9 e1–3.
88. Cilo BD, Agca H, Efe K, Sinirtas M, Celebi S, Ozkan H, et al. Investigation of vancomycin resistant Enterococcus faecium outbreak in neonatal intensive care unit. Int J Clin Exp Med. 2014;7(12):5342–7.
89. Park C, Nichols M, Schrag SJ. Two cases of invasive vancomycin-resistant group B streptococcus infection. N Engl J Med. 2014;370(9):885–6.
90. Heideking M, Lander F, Hufnagel M, Pfeifer Y, Wicker E, Krause G, et al. Antibiotic susceptibility profiles of neonatal invasive isolates of Escherichia coli from a 2-year nationwide surveillance study in Germany, 2009–2010. Eur J Clin Microbiol Infect Dis. 2013;32(9):1221–3.
91. Wade KC, Benjamin DK. Clinical pharmacology of antiinfective drugs. In: Wilson CB, Nizet V, Maldonado YA, Remington JS, Klein JO, editors. Remington and Klein’s infectious diseases of the fetus and newborn infant. 8th ed. Philadelphia: Elsevier; 2016.
92. Nelson’s Pediatric Antimicrobial Therapy. 21st ed. Elk Grove Village (IL): American Academy of Pediatrics; 2015.
93. Shane AL, Hansen NI, Stoll BJ, Bell EF, Sanchez PJ, Shankaran S, et al. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics. 2012;129(4):e914–22.
94. Ericson JE, Popoola VO, Smith PB, Benjamin DK, Fowler VG, Benjamin DK Jr, et al. Burden of invasive Staphylococcus aureus infections in hospitalized infants. JAMA Pediatr. 2015;169(12):1105–11.
95. Chiu CH, Michelow IC, Cronin J, Ringer SA, Ferris TG, Puopolo KM. Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit. Pediatr Infect Dis J. 2011;30(4):273–8.
96. Kim SH, Kim KH, Kim HB, Kim NJ, Kim EC, Oh MD, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52(1):192–7.
97. Huang YC, Chou YH, Su LH, Lien RI, Lin TY. Methicillin-resistant Staphylococcus aureus colonization and its association with infection among infants hospitalized in neonatal intensive care units. Pediatrics. 2006;118(2):469–74.
98. Qu Y, Daley AJ, Istivan TS, Garland SM, Deighton MA. Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation. Ann Clin Microbiol Antimicrob. 2010;9:16.
99. Karlowicz MG, Buescher ES, Surka AE. Fulminant late-onset sepsis in a neonatal intensive care unit, 1988–1997, and the impact of avoiding empiric vancomycin therapy. Pediatrics. 2000;106(6):1387–90.
100. Lawrence SL, Roth V, Slinger R, Toye B, Gaboury I, Lemyre B. Cloxacillin versus vancomycin for presumed late-onset sepsis in the Neonatal Intensive Care Unit and the impact upon outcome of coagulase negative staphylococcal bacteremia: a retrospective cohort study. BMC Pediatr. 2005;5:49.
101. Hemels MA, van den Hoogen A, Verboon-Maciolek MA, Fleer A, Krediet TG. A seven-year survey of management of coagulase-negative staphylococcal sepsis in the neonatal intensive care unit: vancomycin may not be necessary as empiric therapy. Neonatology. 2011;100(2):180–5.
102. Zhou Y, Shan G, Sodergren E, Weinstock G, Walker WA, Gregory KE. Longitudinal analysis of the premature infant intestinal microbiome prior to necrotizing enterocolitis: a case-control study. PLoS One. 2015;10(3):e0118632.
103. Patel RM, Denning PW. Intestinal microbiota and its relationship with necrotizing enterocolitis. Pediatr Res. 2015;78(3):232–8.
104. Greenwood C, Morrow AL, Lagomarcino AJ, Altaye M, Taft DH, Yu Z, et al. Early empiric antibiotic use in preterm infants is associated with lower bacterial diversity and higher relative abundance of Enterobacter. J Pediatr. 2014;165(1):23–9.
105. Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2015;2:CD007137.
106. Dilli D, Aydin B, Fettah ND, Ozyazici E, Beken S, Zenciroglu A, et al. The propre-save study: effects of probiotics and prebiotics alone or combined on necrotizing enterocolitis in very low birth weight infants. J Pediatr. 2015;166(3):545–51 (e1).
107. Vallabhaneni S, Walker TA, Lockhart SR, Ng D, Chiller T, Melchreit R, et al. Notes from the field: fatal gastrointestinal mucormycosis in a premature infant associated with a contaminated dietary supplement—Connecticut, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(6):155–6.
108. Abrahamsson TR. Not all probiotic strains prevent necrotising enterocolitis in premature infants. Lancet (Epub 25 Nov 2015).
109. Liem TB, Krediet TG, Fleer A, Egberts TC, Rademaker CM. Variation in antibiotic use in neonatal intensive care units in the Netherlands. J Antimicrob Chemother. 2010;65(6):1270–5.
110. Shah D, Sinn JK. Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis. Cochrane Database Syst Rev. 2012;8:CD007448.
111. Faix RG, Polley TZ, Grasela TH. A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis. J Pediatr. 1988;112(2):271–7.
112. Hansen TN, Ritter DA, Speer ME, Kenny JD, Rudolph AJ. A randomized, controlled study of oral gentamicin in the treatment of neonatal necrotizing enterocolitis. J Pediatr. 1980;97(5):836–9.
113. Autmizguine J, Hornik CP, Benjamin DK Jr, Laughon MM, Clark RH, Cotten CM, et al. Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants. Pediatrics. 2015;135(1):e117–25.
114. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin N Am. 1986;33(1):179–201.
115. Kurlat I, Stoll BJ, McGowan JE Jr. Time to positivity for detection of bacteremia in neonates. J Clin Microbiol. 1989;27(5):1068–71.
116. Biondi EA, Mischler M, Jerardi KE, Statile AM, French J, Evans R, et al. Blood culture time to positivity in febrile infants with bacteremia. JAMA Pediatr. 2014;168(9):844–9.
117. Jardine L, Davies MW, Faoagali J. Incubation time required for neonatal blood cultures to become positive. J Paediatr Child Health. 2006;42(12):797–802.
118. Cantey JB, Lopez-Medina E, Nguyen S, Doern C, Garcia C. Empiric antibiotics for serious bacterial infection in young infants: opportunities for stewardship. Pediatr Emerg Care. 2015;31(8):568–71.
119. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev. 2014;1:CD003344.
120. Cordero L, Ayers LW. Duration of empiric antibiotics for suspected early-onset sepsis in extremely low birth weight infants. Infect Control Hosp Epidemiol. 2003;24(9):662–6.
121. Spitzer AR, Kirkby S, Kornhauser M. Practice variation in suspected neonatal sepsis: a costly problem in neonatal intensive care. J Perinatol. 2005;25(4):265–9.
122. Wynn JL, Wong HR, Shanley TP, Bizzarro MJ, Saiman L, Polin RA. Time for a neonatal-specific consensus definition for sepsis. Pediatr Crit Care Med. 2014;15(6):523–8.
123. Langley JM, Bradley JS. Defining pneumonia in critically ill infants and children. Pediatr Crit Care Med. 2005;6(3 Suppl):S9–13.
124. Shani L, Weitzman D, Melamed R, Zmora E, Marks K. Risk factors for early sepsis in very low birth weight neonates with respiratory distress syndrome. Acta Paediatr. 2008;97(1):12–5.
125. Weintraub AS, Cadet CT, Perez R, DeLorenzo E, Holzman IR, Stroustrup A. Antibiotic use in newborns with transient tachypnea of the newborn. Neonatology. 2013;103(3):235–40.
126. Ronchi A, Michelow IC, Chapin KC, Bliss JM, Pugni L, Mosca F, et al. Viral respiratory tract infections in the neonatal intensive care unit: the VIRIoN-I study. J Pediatr. 2014;165(4):690–6.
127. Bennett NJ, Tabarani CM, Bartholoma NM, Wang D, Huang D, Riddell SW, et al. Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units. J Pediatr. 2012;161(5):814–8.
128. Kidszun A, Hansmann A, Winter J, Grondahl B, Knuf M, Weise K, et al. Detection of respiratory viral infections in neonates treated for suspicion of nosocomial bacterial sepsis: a feasibility study. Pediatr Infect Dis J. 2014;33(1):102–4.
129. Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet. 2009;48(2):71–88.
130. de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet. 2004;43(7):417–40.
131. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55(9):4277–82.
132. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077–97.
133. McClary JD. Principles of drug use in the fetus and neonate. In: Martin RJ, Fanaroff AA, Walsh MC, editors. Fanaroff and Martin’s neonatal-perinatal medicine. 10th ed. Philadelphia (PA): Elsevier; 2015.
134. Wang J, Edginton AN, Avant D, Burckart GJ. Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling. J Clin Pharmacol. 2015;55(10):1175–83.
135. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J. 2003;22(9 Suppl):S153–7.
136. Gostelow M, Gonzalez D, Smith PB, Cohen-Wolkowiez M. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol. 2014;7(3):327–40.
137. Principi N, Caironi M, Venturini F, Pani L, Esposito S. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother. 2015;70(3):643–8.
138. Ward RM, Kern SE. Clinical trials in neonates: a therapeutic imperative. Clin Pharmacol Ther. 2009;86(6):585–7.
139. O’Hara K, Wright IM, Schneider JJ, Jones AL, Martin JH. Pharmacokinetics in neonatal prescribing: evidence base, paradigms and the future. Br J Clin Pharmacol. 2015;80(6):1281–8.
140. Leroux S, Turner MA, Guellec CB, Hill H, van den Anker JN, Kearns GL, et al. Pharmacokinetic studies in neonates: the utility of an opportunistic sampling design. Clin Pharmacokinet. 2015;54(12):1273–85.
141. Claassen K, Thelen K, Coboeken K, Gaub T, Lippert J, Allegaert K, et al. Development of a physiologically-based pharmacokinetic model for preterm neonates: evaluation with in vivo data. Curr Pharm Des. 2015;21(39):5688–98.
142. Smits A, De Cock RF, Allegaert K, Vanhaesebrouck S, Danhof M, Knibbe CA. Prospective evaluation of a model-based dosing regimen for amikacin in preterm and term neonates in clinical practice. Antimicrob Agents Chemother. 2015;59(10):6344–51.
143. De Cock RF, Allegaert K, Brussee JM, Sherwin CM, Mulla H, de Hoog M, et al. Simultaneous pharmacokinetic modeling of gentamicin, tobramycin and vancomycin clearance from neonates to adults: towards a semi-physiological function for maturation in glomerular filtration. Pharm Res. 2014;31(10):2643–54.
144. US FDA. Food and Drug Administration Safety and Innovation Act. Bethesda (MD): US FDA; 2012. p. 933.
145. The Sanford guide to antimicrobial therapy 2015. 45th ed. London: Ingram; 2015.
146. MacGowan A. Revisiting beta-lactams: PK/PD improves dosing of old antibiotics. Curr Opin Pharmacol. 2011;11(5):470–6.
147. Smuszkiewicz P, Szalek E, Tomczak H, Grzeskowiak E. Continuous infusion of antibiotics in critically ill patients. Curr Clin Pharmacol. 2013;8(1):13–24.
148. Lorente L, Lorenzo L, Martin MM, Jimenez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother. 2006;40(2):219–23.
149. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28(2):122–7.
150. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298–305.
151. Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of beta-lactam antibiotics in the pediatric population. Ann Pharmacother. 2012;46(11):1537–46.
152. Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155–63.
153. Bhongsatiern JJJ, Stockmann C, Roberts JK, Yu T, Korgenski KE, Spigarelli MG, et al. Evaluation of vancomycin use in late-onset neonatal sepsis using the area under the concentration-time curve to the minimum inhibitory concentration ≥400 target. Ther Drug Monit. 2015;37(6):756–65.
154. Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077–9.
155. Sinkeler FS, de Haan TR, Hodiamont CJ, Bijleveld YA, Pajkrt D, Mathot RA. Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations. BMC Pediatr. 2014;14:193.
156. Petrie K, O’Brien C, Bhushan S, Tonna A. Neonatal vancomycin trough level audit using British National Formulary for Children dosing. Arch Dis Child Fetal Neonatal Ed. 2015;100(3):F278–9.
157. Butin M, Rasigade JP, Martins-Simoes P, Meugnier H, Lemriss H, Goering RV, et al. Wide geographical dissemination of the multiresistant Staphylococcus capitis NRCS: a clone in neonatal intensive-care units. Clin Microbiol Infect (Epub 25 Sep 2015).
158. Rasigade JP, Raulin O, Picaud JC, Tellini C, Bes M, Grando J, et al. Methicillin-resistant Staphylococcus capitis with reduced vancomycin susceptibility causes late-onset sepsis in intensive care neonates. PLoS One. 2012;7(2):e31548.
159. Zhao W, Lopez E, Biran V, Durrmeyer X, Fakhoury M, Jacqz-Aigrain E. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring. Arch Dis Child. 2013;98(6):449–53.
160. Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Roze JC. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol. 1998;46(2):163–7.
161. Samiee-Zafarghandy S, van den Anker JN. Do we really need continuous vancomycin infusion in neonates? Arch Dis Child. 2013;98(12):1023–4.
162. Madigan T, Teng CB, Koshaish J, Johnson KR, Graner KK, Banerjee R. Optimization of vancomycin dosing in very low-birth-weight preterm neonates. Am J Perinatol. 2015;32(1):83–6.
163. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.
164. Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J. 2010;29(9):827–30.
165. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39(6):677–86.
166. Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2011;11:CD005091.
167. Skopnik H, Heimann G. Once daily aminoglycoside dosing in full term neonates. Pediatr Infect Dis J. 1995;14(1):71–2.
168. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004;114(1):e111–8.
169. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.
170. van Buul LW, Sikkens JJ, van Agtmael MA, Kramer MH, van der Steen JT, Hertogh CM. Participatory action research in antimicrobial stewardship: a novel approach to improving antimicrobial prescribing in hospitals and long-term care facilities. J Antimicrob Chemother. 2014;69(7):1734–41.
171. Patel S, Landers T, Larson E, Zaoutis T, Delamora P, Paul DA, et al. Clinical vignettes provide an understanding of antibiotic prescribing practices in neonatal intensive care units. Infect Control Hosp Epidemiol. 2011;32(6):597–602.
172. Shipp KD, Chiang T, Karasick S, Quick K, Nguyen ST, Cantey JB. Antibiotic stewardship challenges in a referral neonatal intensive care unit. Am J Perinatol (Epub 18 Dec 2015).